These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7525868)

  • 21. The role of the globus pallidus D2 subfamily of dopamine receptors in pallidal immediate early gene expression.
    Marshall JF; Henry BL; Billings LM; Hoover BR
    Neuroscience; 2001; 105(2):365-78. PubMed ID: 11672604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain neuropeptides in progressive supranuclear palsy.
    Taquet H; Javoy-Agid F; Mauborgne A; Benoliel JJ; Agid Y; Legrand JC; Hamon M; Cesselin F
    Brain Res; 1987 May; 411(1):178-82. PubMed ID: 2440513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.
    Betarbet R; Greenamyre JT
    Exp Neurol; 2004 Oct; 189(2):393-403. PubMed ID: 15380489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurotransmitter receptor alterations in Huntington's disease: autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes.
    Whitehouse PJ; Trifiletti RR; Jones BE; Folstein S; Price DL; Snyder SH; Kuhar MJ
    Ann Neurol; 1985 Aug; 18(2):202-10. PubMed ID: 2994554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Further characterization of preproenkephalin mRNA-containing cells in the rodent globus pallidus.
    Hoover BR; Marshall JF
    Neuroscience; 2002; 111(1):111-25. PubMed ID: 11955716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. I. Effects of intranigral or intracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine system.
    Joyce JN
    Exp Neurol; 1991 Sep; 113(3):261-76. PubMed ID: 1833219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
    Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
    Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP.
    Tanji H; Araki T; Nagasawa H; Itoyama Y
    Brain Res; 1999 Apr; 824(2):224-31. PubMed ID: 10196452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients.
    Knable MB; Hyde TM; Herman MM; Carter JM; Bigelow L; Kleinman JE
    Biol Psychiatry; 1994 Dec; 36(12):827-35. PubMed ID: 7893846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cocaine exposure in fetal rhesus monkey: consequences for dopamine D1- and D2-like receptor binding densities.
    Fang Y; Janowsky A; Rønnekleiv OK
    Brain Res Dev Brain Res; 1997 Dec; 104(1-2):163-74. PubMed ID: 9466719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of neurotensin-containing neurons in the rat striatum and substantia nigra. Effects of unilateral nigral lesion with 6-hydroxydopamine on neurotensin content and its binding site density.
    Masuo Y; Pélaprat D; Montagne MN; Scherman D; Rostène W
    Brain Res; 1990 Mar; 510(2):203-10. PubMed ID: 1970504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease cases.
    Joyce JN
    Brain Res; 1993 Jan; 600(1):156-60. PubMed ID: 8422582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DA uptake sites, D1 and D2 receptors, D2 and preproenkephalin mRNAs and Fos immunoreactivity in rat striatal subregions after partial dopaminergic degeneration.
    Chritin M; Blanchard V; Raisman-Vozari R; Feuerstein C; Agid Y; Javoy-Agid F; Savasta M
    Eur J Neurosci; 1996 Dec; 8(12):2511-20. PubMed ID: 8996800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset.
    Svenningsson P; Gunne L; Andren PE
    Neuroscience; 2000; 99(3):457-68. PubMed ID: 11029538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
    Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
    Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
    Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rats bred for enhanced apomorphine susceptibility have elevated tyrosine hydroxylase mRNA and dopamine D2-receptor binding sites in nigrostriatal and tuberoinfundibular dopamine systems.
    Rots NY; Cools AR; Bérod A; Voorn P; Rostène W; de Kloet ER
    Brain Res; 1996 Feb; 710(1-2):189-96. PubMed ID: 8963658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenotypical characterization of the neurons expressing the D1 and D2 dopamine receptors in the monkey striatum.
    Aubert I; Ghorayeb I; Normand E; Bloch B
    J Comp Neurol; 2000 Feb; 418(1):22-32. PubMed ID: 10701753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Visualization of dopamine D1, D2 and D3 receptor mRNAs in human and rat brain.
    Mengod G; Villaró MT; Landwehrmeyer GB; Martinez-Mir MI; Niznik HB; Sunahara RK; Seeman P; O'Dowd BF; Probst A; Palacios JM
    Neurochem Int; 1992 Mar; 20 Suppl():33S-43S. PubMed ID: 1365451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of striatal high affinity NGF binding sites in progressive supranuclear palsy but not in Parkinson's disease.
    Villares J; Strada O; Faucheux B; Javoy-Agid F; Agid Y; Hirsch EC
    Neurosci Lett; 1994 Nov; 182(1):59-62. PubMed ID: 7891888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.